The Relevance of the Siewert Classification in the Era of Multimodal Therapy for Adenocarcinoma of the Gastro-Oesophageal Junction

NATHAN J. CURTIS,1,2 FERGUS NOBLE,1,2 JAN S. BAILEY, MS, FRCS,1 JAMIE J. KELLY, FRCS,1 JAMES P. BYRNE, MD, FRCS,1 AND TIMOTHY J. UNDERWOOD, PhD, FRCS1,2*

1Department of Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, UK
2Cancer Sciences Unit, Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, UK

Introduction: The Siewert classification has been used to plan treatment for tumours of the gastro-oesophageal junction since its proposal in the 1980s. The purpose of this study was to assess its continued relevance by evaluating whether there were differences in the biology and clinical characteristics of adenocarcinomas by Siewert type, in a contemporary cohort of patients, in whom the majority had received neoadjuvant chemotherapy.

Methods: A prospective database was reviewed for all patients who underwent resection from 2005 to 2011 and analysed with regard to Siewert classification determined from the pathological specimen, treatment and clinicopathological outcomes.

Results: Two hundred and sixteen patients underwent oesophago-gastric resection: 133 for type I, 51 for type II and 33 for type III tumours. 135 Patients (62.5%) received neoadjuvant chemotherapy with no difference between groups. There were no significant differences in age, sex, pT stage, pN stage, pM stage, ASA, or inpatient complications between patients with adenocarcinoma based on their Siewert classification. There was a significant increase in maximum tumour diameter (P = 0.023), perineural invasion (P = 0.021) and vascular invasion (P = 0.020), associated with more distal tumours (Type III > Type II > Type I). Median overall survival was significantly shorter for more distal tumours (Type I: 4.96 years vs. Type II: 3.3 years vs. Type III: 2.64 years; P = 0.04). The surgical approach did not influence survival.

Conclusion: In the era of multi-modal treatment pathological Siewert tumour type is of prognostic value, as patients with Type III disease are likely to have larger and more aggressive tumours that lead to worse outcomes.

J. Surg. Oncol. 2014;109:202–207. © 2013 The Authors. Journal of Surgical Oncology Published by Wiley Periodicals, Inc.

Key Words: Siewert classification; oesophageal cancer; oesophagectomy; surgical approach

INTRODUCTION

Since the 1980s, the Siewert classification has been used to plan treatment for adenocarcinomas arising from the gastro-oesophageal junction (GOJ). In an attempt to promote diagnostic homogeneity, Siewert described a system based on the relationship between the tumour origin and the GOJ evaluated at endoscopy prior to resection [1]. Tumours whose epicentre was in the distal oesophagus were grouped as Siewert I, carcinoma immediately arising at the GOJ were considered Siewert II and subcardial carcinoma of the fundus called Siewert III. This classification has subsequently been used in staging and selection of the surgical approach to tumour resection [2]. Many aspects of attempting GOJ tumour classification have attracted criticism. The GOJ is an artificial division between two organs that remains difficult to accurately localise at endoscopy, radiologically or by laparoscopic assessment and inter-observer divergence has been shown [3–5]. The presence of Barrett’s oesophagus, hiatus hernia or the tumour itself may distort the anatomical findings. Also, large tumours may straddle two Siewert groups and the epicentre may be hard to define [3]. Patterns of lymph node spread have been shown to vary from group to group in the oesophageal and makes no attempt to subclassify tumours based on their anatomical topographical origin [10]. TNM7 was developed using complex computational modelling in an attempt to provide accurate prognostication for each homogeneous stage group [11]. However, the dataset included mostly patients treated with surgery alone and was based on pathological staging.

The multidisciplinary management of GOJ tumours has evolved since the introduction of the Siewert classification. Whilst widespread improvements in pre-operative staging [12], patient selection [13], critical care [14], nutritional support and surgical techniques [15] have been made, some groups advocate a tailored approach to GOJ tumours with the belief that Siewert III tumours represent true gastric cancer and are better treated with total gastrectomy and D2 lymphadenectomy [8].

The most recent revision of the Tumour, Node, Metastasis Classification system (TNM7), for oesophageal cancer has attempted to bring uniformity to the assessment of GOJ tumours. TNM7 [9] classifies all tumours within 5 cm of the GOJ which extend into the oesophagus as oesophageal and makes no attempt to subclassify tumours based on their anatomical topographical origin [10]. TNM7 was developed using complex computational modelling in an attempt to provide accurate prognostication for each homogeneous stage group [11]. However, the dataset included mostly patients treated with surgery alone and was based on pathological staging.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Presented in part at the Digestive Disorders Federation Conference, Liverpool, UK 17th–20th June 2012.

TJU is funded by the Medical Research Council (UK)

Conflits of interest: none.

*Correspondence to: Mr. T.J. Underwood, Cancer Sciences Unit, University of Southampton, Somers Cancer Research Building, MIPS24, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK. E-mail: t.j.underwood@soton.ac.uk

Received 06 June 2013; Accepted 10 October 2013

DOI 10.1002/jso.23484

Published online 14 November 2013 in Wiley Online Library (wileyonlinelibrary.com).

© 2013 Wiley Periodicals, Inc.
including laparoscopic surgery [16] have been made, arguably the largest single change in the management of GOJ tumours has been the application of neoadjuvant therapy [17]. Multimodal treatment has been reported to increase R0 resection rates through tumour down staging [18,19], decrease the number of involved lymph nodes [20,21] and improve long-term survival compared to surgery alone [17–19,22–24]. Pathological complete response (pCR) to chemoradiotherapy has been reported [25,26] with selected studies demonstrating pCR in around 20–30% of patients [18,21]. Neoadjuvant treatments for GOJ tumours are now in widespread use around the world.

The changes made in TNM7 and the widespread use of neoadjuvant therapies for GOJ tumours questions the relevance of a classification that was established when most tumours were treated with surgery alone. Therefore, the purpose of this study was to evaluate whether there were differences in the biology and clinical characteristics of adenocarcinomas of the GOJ when classified by Siewert type, in a contemporary cohort of patients receiving multi-modal therapy.

METHODS

A prospectively collected database of consecutive patients undergoing oesophagogastrectomy for tumours of the GOJ treated at a single UK university teaching hospital between January 2005 and December 2011 was reviewed. All patients were discussed at a specialist multidisciplinary team meeting. Standard staging investigations included endoscopic ultrasonography, high-resolution computed tomography, integrated fluorodeoxyglucose positron emission tomography/computed tomography (PET-CT) and staging laparoscopy where indicated. Patients considered suitable for surgical resection with tumours staged as T2 N0 M0 or above were considered for neoadjuvant chemotherapy that was uniformly applied irrespective of tumour location. Our regime consists of three 21-day cycles of EC (Epirubicin 50 mg/m², Cisplatin 60 mg/m², both intravenously on day 1 and protracted venous infusion 5-FU 200 mg/m² per day) or ECX (Epirubicin 50 mg/m², Cisplatin 60 mg/m², both intravenously on day 1 and Oxaliplatin 625 mg/m² orally twice daily for 21 days) or EOX (Epirubicin 50 mg/m² i.v. bolus and Oxaliplatin 130 mg/m² i.v. infusion over 2 hr on day 1, Cepacitabine 625 mg/m² orally twice daily for 21 days).

In our unit, based on pre-operative assessment, Siewert type I and II tumours are treated as oesophageal cancer, with transthoracic procedures. Type III tumours are treated as gastric cancers with an abdominal approach, typically, total gastrectomy, distal oesophagectomy and D2 lymphadenectomy. All patients considered to have a type III tumour pre-operatively underwent staging laparoscopy. Types of oesophagogastrectomies included Ivor-Lewis, left thoracoabdominal with or without cervical Anastomosis, and transthiatal oesophagogastrectomy or minimally invasive oesophagogastrectomy either 2 stage (MIO-2) or 3 stage (MIO-3). Patients were cared for by a specialist oesophagogastrectomy team who applied a similar perioperative regime to all.

Patients were routinely followed up for 5 years post-surgery and were also seen on as required basis if symptomatic. Recurrence of disease during follow-up was defined as the first site or sites of recurrence with radiological or pathological confirmation. Site of recurrence was defined as local: anastomosis or local lymph nodes, nodal: regional lymph nodes and distant: distant nodal or distant organ recurrence.

Data recorded included demographics, tumour characteristics, type of resection, histopathological analysis of the surgical specimen, post-operative complications and mortality. Classification systems used for analysis included TNM7 [8,9], Clavien-Dindo [27], tumour regression grade (TRG) [28] and Siewert [1] using the final tumour site determined from the pathological specimen. Pathological tumour clearance (‘R’-status) was determined according to the Royal College of Pathologists of England system.

Kruskal–Wallis, Mann–Whitney U and Pearson’s χ² tests were used. A P-value < 0.05 was considered significant. Overall survival was analysed by the Kaplan–Meier method calculated from the date of operation until the date of death excluding inpatient deaths (n = 4) and R1 resections (n = 42). Statistical analysis was performed with SPSS® version 19 (SPSS, Chicago, IL).

RESULTS

Two hundred and sixteen patients underwent oesophagogastrectomy: 132 for type I, 51 for type II and 33 for type III tumours. One hundred and thirty-five (62.5%) underwent neoadjuvant chemotherapy prior to resection. The majority of patients were male (85.6%) but there were no significant differences in age, sex, ASA or neoadjuvant use between patients with adenocarcinoma based on their Siewert classification (Table I). Barrett’s oesophagus was observed most commonly in association with type I tumours (Type I 58.3%, Type II 21.6%, Type III 9.1%; P < 0.0001).

Surgical approaches varied by Siewert group (Table I). As determined by analysis of the pathological specimen, 96.2% of Siewert I tumours had a transthoracic procedure compared to 45.5% for type III tumours. Of the 33 Siewert III specimens, 14 (42%) were pre-operatively staged as more proximal disease and all of these patients underwent a transthoracic operation. Seventy-eight percent of Type III tumours resected via an abdominal approach were staged as T3 or T4 on the pathological specimen, compared with 33% via a transthoracic approach (P = 0.04). However, there were no other significant differences observed for Type III tumours dependent on surgical approach (or ypN-stage, nodal yield, R0/R1 resection rate, anastomotic leak rate, post-operative complications or survival). Local, nodal and distant recurrences were more common in distal tumours (Table II). One hundred and forty-one (65.2%) cases were performed laparoscopically. The surgical approach did not impact on the frequency or severity of post-operative complications. Patients (22.6%) developed a major complication (CD 3–5). The overall anastomotic leak rate was 7.4%, with no differences between surgical approach or Siewert tumour type. Four inpatient deaths (1.8%) were recorded, all following transthoracic surgery (Table III).

Histopathological assessment showed no differences in tumour differentiation, p or ypT (P = 0.80), p or ypN (P = 0.36), number of positive lymph nodes, p or ypM (0.828) or R1 resections between the groups (Table IV). 19.4% of Resections were classified as R1 using the Royal College of Pathologists of England system. More distal tumours were significantly bigger (mean tumour diameter, Type I: 25.8 mm, Type II: 33.1 mm, Type III: 35.6 mm, P = 0.023), more likely to show vascular (P = 0.02) and perineural invasion (P = 0.021) and were associated with a higher lymph node harvest (median nodal harvest; Type I: 17, Type II: 20, Type III: 23, P = 0.004), although the number of lymph node metastasis did not differ between tumour types. In 25%, of patients treated with neoadjuvant chemotherapy significant tumour response was observed in the resected specimen (TRG 1–2) and there was no difference in the likelihood of observing tumour regression based on Siewert tumour type (P = 0.676).

Median follow-up was 2.94 years. Median overall survival for the full cohort was 3.4 years (95% confidence interval (CI) 2.14–4.66). Median overall survival was significantly shorter for more distal tumours (Type I: 4.96 years (95% CI: 4.12–5.23) vs. Type II: 3.3 years (95% CI: 2.63–4.04) vs. Type III: 2.64 years (2.04–3.63); P = 0.04). The surgical approach did not influence survival for all tumour types. Three-year overall survival was significantly better for more proximal tumours and decreased for more distal tumours (Type I: 78%, Type II: 60% HR 1.54 (95% CI: 0.81–2.92), Type III: 37% HR 2.28 (95% CI: 1.17–4.45); P = 0.011 (Fig. 1)).

DISCUSSION

Multidisciplinary experience in the management of GOJ adenocarcinomas has progressed since the Siewert classification was
TABLE I. Patient Demographics, American Society of Anesthesiologists Physical Status Classification System Score and Presence of Barrett’s Metaplasia, Treatment Plans, Surgical Approach and Operation Performed by Siewert Groups

|                        | Siewert I (n = 132) | Siewert II (n = 51) | Siewert III (n = 33) |
|------------------------|---------------------|---------------------|---------------------|
|                        | Median   | Min    | Max    | Median   | Min    | Max    | Median   | Minimum | Maximum | Count | Column, N % | P-value |
| Age at Op              | 67.6     | 42.1   | 84.1   | 64.3     | 32.8   | 82.5   | 67.6     | 50.7    | 85.4    | ns    | ns         | ns      |
| Sex                    |          |        |        |          |        |        |          |         |         |       |            | ns      |
| Male                   | 113      | 85.6%  |        | 45       | 88.2%  |        | 27       | 81.8%   |         |       | ns         | ns      |
| Female                 | 19       | 14.4%  |        | 6        | 11.8%  |        | 6        | 18.2%   |         |       |            |         |
| Barrett’s              |          |        |        |          |        |        |          |         |         |       | ns         |         |
| Yes                    | 77       | 58.3%  |        | 11       | 21.6%  |        | 3        | 9.1%    |         |       |            |         |
| No                     | 55       | 41.7%  |        | 40       | 78.4%  |        | 30       | 90.1%   |         |       |            |         |
| ASA                    |          |        |        |          |        |        |          |         |         |       | ns         |         |
| 1                      | 8        | 6.1%   |        | 3        | 5.9%   |        | 3        | 9.1%    |         |       |            |         |
| 2                      | 100      | 76.3%  |        | 37       | 72.5%  |        | 23       | 69.7%   |         |       |            |         |
| 3                      | 23       | 17.6%  |        | 11       | 21.6%  |        | 7        | 21.2%   |         |       |            |         |
| Treatment              |          |        |        |          |        |        |          |         |         |       | ns         | ns      |
| Surgery only           | 51       | 38.6%  |        | 18       | 35.3%  |        | 12       | 36.4%   |         |       |            |         |
| Neoadjuvant chemotherapy and surgery | 81 | 61.4% | | 33 | 64.7% | | 21 | 36.6% | | | | |
| Transthoracic vs. abdominal |          |        |        |          |        |        |          |         |         |       | ns         |         |
| Transthoracic          | 127      | 96.2%  |        | 50       | 98.0%  |        | 15       | 45.5%   |         | <0.0001 |          |
| Abdomen                | 5        | 3.8%   |        | 1        | 2.0%   |        | 18       | 54.5%   |         | <0.0001 |          |
| Operation type         |          |        |        |          |        |        |          |         |         |       |            |         |
| Ivor-Lewis             | 33       | 25.0%  |        | 20       | 39.2%  |        | 3        | 9.1%    |         | <0.0001 |          |
| Minimally invasive oesophagectomy—2 stage | 46 | 34.8% | | 17 | 33.3% | | 7 | 21.2% | | | | |
| Minimally invasive oesophagectomy—3 stage | 20 | 15.2% | | 5 | 9.8% | | 3 | 9.1% | | | | |
| Left thoracoabdominal  | 28       | 21.2%  |        | 8        | 15.7%  |        | 2        | 6.1%    |         |       |            |         |
| Laparoscopic gastrectomy + distal oesophagectomy | 0 | 0.0% | | 1 | 2.0% | | 4 | 12.1% | | | | |
| Open D2 gastrectomy + distal oesophagectomy | 5 | 3.8% | | 0 | 0.0% | | 14 | 42.4% | | | | |
first reported. TNM7 now classifies all tumours within 5 cm of the GOJ, which involves the oesophagus as oesophageal, and makes no distinction between tumours that may be considered to arise from adjacent but different organs (the oesophagus and stomach). The results of multiple randomised trials, published since 2000, strongly support the use of perioperative therapy for tumours of the GOJ with a consequent marked increase in R0 resection rate and long-term survival with an acceptable short-term side effect profile [18,19,22-24]. In our centre, the majority of patients (65.2%) who are suitable for curative resection received multimodal therapy. Given this differs from the 17% in the original Siewert reports [2] our study is relevant for contemporary practice.

In contrast to previous reports, Type I tumours made up 61% of our cohort. Siewert and Leers have previously reported 37% [2] and 50% [3] respectively from large single centre western series compared to the low prevalence of type III tumours seen in eastern series (5.6%) [29]. The proportional increase in Type I tumours in our series is likely to represent the widely reported increase in incidence of oesophageal adenocarcinoma [30,31] associated with gastro-oesophageal reflux disease [32] and Barrett’s metaplasia [33] in the United Kingdom [34]. The expansion of endoscopic Barrett’s surveillance strategies is also likely to have increased disease detection and treatment. Similarly, the decrease in type III cases follows the reduction in incidence of true gastric adenocarcinomas observed in the West [35].

### TABLE II. Tumour Recurrences by Location

| Tumour site by Siewert classification | Siewert I (n = 132) | Siewert II (n = 51) | Siewert III (n = 33) |
|--------------------------------------|---------------------|---------------------|---------------------|
| Local recurrence                     |                     |                     |                     |
| Yes                                  | 6                   | 4.5%                | 1                   | 2.0%                | 2                   | 6.1%                |
| No                                   | 126                 | 95.5%               | 50                  | 98.0%               | 31                  | 93.9%               |
| Nodal recurrence                     |                     |                     |                     |
| Yes                                  | 10                  | 7.6%                | 2                   | 3.9%                | 6                   | 18.2%               |
| No                                   | 122                 | 92.4%               | 49                  | 96.1%               | 27                  | 81.8%               |
| Distant recurrence                   |                     |                     |                     |
| Yes                                  | 34                  | 25.6%               | 18                  | 35.3%               | 8                   | 24.2%               |
| No                                   | 98                  | 74.4%               | 33                  | 64.7%               | 25                  | 75.8%               |

P = ns.

### TABLE III. Post-Operative Complications and Anastomotic Leak Data

| Transhiatral vs. abdominal | Transthoracic | Abdominal | P-value |
|---------------------------|--------------|-----------|---------|
| Major or minor            |              |           |         |
| Minor or no comp          | 145          | 76.0%     | 21      | 87.5%   | ns |
| Major or death            | 46           | 24.0%     | 3       | 12.5%   | |
| Clavien Dindo Classification |            |           |         |
| No complication           | 69           | 35.9%     | 11      | 45.8%   | ns |
| Grade 1                   | 12           | 6.3%      | 1       | 4.2%    | |
| Grade 2                   | 64           | 33.3%     | 9       | 37.5%   | |
| Grade 3                   | 22           | 11.5%     | 2       | 8.3%    | |
| Grade 4                   | 21           | 10.9%     | 2       | 8.3%    | |
| Grade 5                   | 4            | 2.1%      | 0       | 0.0%    | |
| None or minor or major complication | 69 | 35.9% | 11 | 45.8% | ns |
| Minor                     | 77           | 40.1%     | 10      | 41.2%   | |
| Major                     | 46           | 24.0%     | 3       | 12.5%   | |

| Siewert I | Siewert II | Siewert III | P-value |
|-----------|-----------|-------------|---------|
| Anastomotic leaks |       |             |         |
| Yes        | 10        | 7.6%        | 4       | 7.8%    | 2       | 6.3%    | ns |
| No         | 122       | 92.4%       | 47      | 92.2%   | 31      | 93.9%   | |

We have demonstrated an overall 5-year survival of >40% with the use of multimodal therapy for tumours of the GOJ. This compares well with the outcomes reported in other large single centre series [2,3]. We have further demonstrated that survival is worse for more distal tumours; patients with pathologically defined Type III tumours are less than half as likely to be alive at 3 years when compared to distal oesophageal tumours. We are not the first to report a biological difference between tumours at the GOJ [2,3,5,36]. In our series, Type III tumours were larger and they were associated with more frequent evidence of perineural and vascular invasion, although this did not translate into more lymph node metastasis. Whilst this may indicate the type III tumours in this series were of a more advanced stage at presentation, this did not reach statistical significance (pT (P = 0.080), pN (0.367), pM (0.828) and AJCC stage grouping (P = 0.508)). This suggests a possible difference in the biological behaviour of GOJ tumours based on their anatomical origin. In this series Type III tumours were equally likely to recur in a loco-regional setting as they were at distant sites when compared with Type I and II tumours that recurred at distant sites in ~80–90% of cases. This finding was not dependent on the operative approach taken to Type III tumours.

One possible explanation for this finding is the anatomical setting of the distal oesophagus when compared with the proximal stomach. A tumour whose epicentre is in the distal oesophagus or at the GOJ may be more likely to give rise to symptoms (dysphagia) at an earlier stage in disease evolution than a proximal gastric cancer that invades into the GOJ as it develops. Furthermore, adjacent organs limit the local spread of oesophageal tumours and operable tumours will be resected en bloc with local lymph nodes and surrounding tissue. It is our practice to routinely take a cuff of hiatal tissue and clear the peritoneum anteriorly and aorta posteriorly. Tumours in the abdomen are not bounded in the same way and may spread into the peritoneal cavity. We routinely perform peritoneal lavage for cytology for Type III tumours as part of our pre-operative work-up, but this strategy has been documented to have limited accuracy [37]. Another possible explanation for a higher loco-regional recurrence rate for Type III tumours would be inadequate surgery leading to R1 resections. Our R1 resection rate of 19% is based on the definition of an R1 resection from the Royal College of Pathologists of England, using the American system the proportion of R1 resections fails to 10%, an improvement on the 27% reported by Siewert [2] and comparable to the 7% reported by DeMeester and coworkers [3]. There were no differences in R1 resection rates between Siewert tumour types.

Given the fact that tumours within 5 cm of the GOJ are now all classified as oesophageal and treated the same pathologically, our findings add to concerns that Siewert III tumours may be biologically different from tumours of the distal oesophagus and GOJ. Epidemiological data supports the concept that GOJ tumours are oesophageal in origin [35] and therefore our histologically proven Siewert III cases may represent true gastric adenocarcinoma. If so, direct comparison with other GOJ tumours for prognostication may be inaccurate. Even if tumours around the GOJ represent similar biological entities our data suggest that Siewert III tumours tend to be larger at presentation and patients with these tumours are far less likely to be alive 3 years after surgery than patients with more proximal disease, despite multimodal therapy. This is the important information for the patients and their families (3-year survival: Type I: 78%, Type II: 60% HR 1.54 (95% CI 0.81–2.92), Type III: 37% HR 2.28 (95% CI 1.17–4.45); P = 0.011 (Fig. 1)).

Our data should be regarded with caution because although the total number of resections performed was not inconceivable and the series benefits from originating at a single centre with defined treatment pathways, the number of Type III tumours was relatively small (n = 33). No differences in pT stage were seen between the Siewert groups (P = 0.08) but low Siewert III numbers may have resulted in a type II error. Further, insufficient numbers of Type III tumours prevents full risk stratification analysis by disease stage. The
The pattern of disease reported in this series represents the current trends of GOJ cancer in the United Kingdom and the findings are relevant for the contemporary treatment of adenocarcinoma of the distal oesophagus and GOJ.

This series also highlights one of the major problems with the Siewert classification, the relative inability of experienced oesophageal physicians to accurately distinguish the epicentre of tumours around the GOJ on pre-operative assessment [5,29]. In our cohort, 42% of pathologically proven Type III tumours were designated as more proximal disease during the pre-operative work-up. The majority were defined as Type II tumours and therefore underwent a transthoracic procedure. The outcomes for these patients were similar to those who underwent an abdominal approach and this finding would lend support to the belief that all GOJ tumours may be adequately treated by an oesophagectomy [3]. It is possible that the true epicentre of the tumour is better revealed after neoadjuvant treatment and we are therefore better able to accurately identify Siewert type on the resected specimen.

Overall, in the era of multi-modal treatment, in an expert centre, the pre-operative Siewert classification is difficult to assess and corresponds poorly to the resected specimen. The surgical approach to Siewert type III tumours of the GOJ in this series did not appear to change short- and long-term outcome. However, knowing the pathological Siewert group is of considerable prognostic value, as patients with progressively more distal disease were seen to have larger and more aggressive tumours that led to worse outcomes. These findings have implications for research and clinical trials as well as prognosis following resection.

REFERENCES

1. Siewert JR, Holscher AH, Becker K, et al.: [Cardia cancer: Attempt at a therapeutically relevant classification]. Chirurg 1987;58:25–32.
2. Rudiger SJ, Feith M, Werner M, et al.: Adenocarcinoma of the esophagogastric junction: Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000;232:353–361.
3. Leers JM, DeMeester SR, Chan N, et al.: Clinical characteristis, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg 2009;138:594–602.
4. Grootenhuis BA, Wijnhoven BP, Poley JW, et al.: Preoperative assessment of tumor location and station-specific lymph node status.

---

**TABLE IV. Histopathological Analysis Results**

|          | Siewert I (n = 132) | Siewert II (n = 51) | Siewert III (n = 33) |
|----------|---------------------|---------------------|---------------------|
| pT TNM7  | Median Min Max Count N % | Median Min Max Count N % | Median Min Max Count N % |
| T0       | 6 4.5% | 1 2.0% | 2 6.1% ns (0.08) |
| T1       | 35 26.5% | 7 13.7% | 4 12.1% |
| T2       | 28 21.2% | 15 29.4% | 8 24.2% |
| T3       | 61 46.2% | 26 51.0% | 13 39.4% |
| T4       | 1 0.8% | 2 3.9% | 6 18.2% |
| pN TNM7  | 74 56.1% | 23 45.1% | 15 45.5% ns |
| N0       | 23 17.4% | 12 23.5% | 5 15.2% |
| N1       | 17 12.9% | 12 23.5% | 7 21.2% |
| N2       | 18 13.6% | 4 7.8% | 6 18.2% |
| N3       | 129 97.7% | 49 96.1% | 32 97.0% ns |
| pM TNM7  | 3 2.3% | 2 3.9% | 1 3.0% |
| Nodes +ve| 0 0 20 | 1 0 15 | 1 0 24 |
| Nodal yield| 17 3 52 | 20 7 53 | 23 7 49 |
| Pathological tumor clearance | 4 12.1% ns |
| R0       | 105 79.5% | 40 78.4% | 29 87.9% |
| Vascular invasion | 14 42.4% 0.020 |
| Yes      | 30 22.7% | 20 39.2% | 14 42.4% |
| No       | 102 77.3% | 31 60.8% | 19 57.6% |
| Lymphatic invasion | 4 12.1% |
| Yes      | 17 12.9% | 9 17.6% | 4 12.1% |
| No       | 115 87.1% | 42 82.4% | 29 87.9% |
| Perineural invasion | 6 18.2% 0.021 |
| Yes      | 10 7.6% | 11 21.6% | 6 18.2% |
| No       | 122 92.4% | 40 78.4% | 27 81.8% |
| Differentiation/grade | 1 3.0% ns |
| Grade 1  | 16 12.1% | 4 7.8% | 1 3.0% |
| Grade 2  | 39 29.5% | 20 39.2% | 8 24.2% |
| Grade 3  | 77 58.3% | 26 51.0% | 24 72.7% |
| Grade 4  | 0 0.0% | 1 2.0% | 0 0.0% |

Fig. 1. Kaplan–Meier graph showing overall survival by Siewert grouping (P = 0.04).

*Journal of Surgical Oncology*
in patients with adenocarcinoma of the gastroesophageal junction. World J Surg 2013;37:147–155.

5. Reeh M, Mina S, Bockhorn M, et al.: Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction. Br J Surg 2012;99:1406–1414.

6. Feith M, Stein HJ, Siewert JR: Pattern of lymphatic spread of Barrett’s cancer. World J Surg 2003;27:1052–1057.

7. Siewert JR, Stein HJ, Feith M: Surgical approach to invasive adenocarcinoma of the distal esophagus (Barrett’s cancer). World J Surg 2003;27:1058–1061.

8. Japanese Gastric Cancer Association: Japanese gastric cancer treatment guidelines 2010 (v3). Gastric Cancer 2011;14:113–123.

9. Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM Classification of Malignant Tumors. 7th edition. Wiley-Blackwell; 2009.

10. Reid TD, Sanyaolu LN, Chan D, et al.: Relative prognostic value of TNM7 vs TNM6 in staging oesophageal cancer. Br J Cancer 2011;105:842–846.

11. Rice TW, Rusch VW, Ishikawa H, et al.: Cancer of the esophagus and esophagogastric junction. Cancer 2010;116:3763–3773.

12. Noble F, Bailey D, Tung K, et al.: Impact of integrated PET/CT in the staging of oesophageal cancer: A UK population-based cohort study. Clin Radiol 2009;64:699–705.

13. Stein HJ, Sendler A, Fink U, et al.: Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am 2000;80:659–682.

14. Bachmann MO, Alderson D, Edwards D, et al.: Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers. Br J Surg 2002;89:914–922.

15. Lauder CI, Marlow NE, Maddern GJ, et al.: Systematic review of the impact of volume of oesophagectomy on patient outcome. ANZ J Surg 2010;80:317–323.

16. Biero SS, van Berge Henegouwen MI, Maas KW, et al.: Miminally invasive versus open oesophagectomy for patients with oesophageal cancer: A multicentre, open-label, randomised controlled trial. Lancet 2012;379:1887–1892.

17. Matuschek C, Bolke E, Peiper M, et al.: The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. Eur J Med Res 2011;16:265–274.

18. van HP, Hulshof MC, van Lanschot JJ, et al.: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–2084.

19. Schuhmacher C, Gretschel S, Lordick F, et al.: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010;28:5210–5218.

20. Castern C, Scarpa M, Capoglu M, et al.: Nodal metastasis from locally advanced esophageal cancer: How neoadjuvant therapy modifies their frequency and distribution. Ann Surg Oncol 2011;18:3743–3754.

21. Zemanova M, Petruzelka L, Pazdro A, et al.: Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: Long-term follow-up. Dis Esophagus 2010;23:160–167.

22. Allum WH, Stenning SP, Bancewicz J, et al.: E. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Clin Oncol 2009;27:5062–5067.

23. van Heijl M, van Lanschot JJ, Koppert LB, et al.: Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 2008;8:21.

24. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.

25. Watanabe T, Yoshikawa T, Kameda Y, et al.: Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: Report of a case. Surg Today 2012;42:983–987.

26. Takahashi K, Kawasaki H, Wajima N, et al.: [Two cases of complete response of primary esophageal carcinoma treated with 5-FU/ CDDP as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho 2011;38:2394–2396.

27. Clavien PA, Barkun J, de Oliveira ML, et al.: The Clavien-Dindo classification of surgical complications: Five-year experience. Ann Surg 2009;250:187–196.

28. Mandard AM, Dalibard F, Mandard JC, et al.: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinico-pathologic correlations. Cancer 1994;73:2680–2686.

29. Hosokawa Y, Kinoshita T, Konishi M, et al.: Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: Experiences at a single institution in Japan. Ann Surg Oncol 2012;19:677–683.

30. Blot WJ, Devesa SS, Kneller RW, et al.: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287–1289.

31. DeMeester SR: Adenocarcinoma of the esophagus and cardia: A review of the disease and its treatment. Ann Surg Oncol 2006;13:12–30.

32. Lagergren J, Bergstrom R, Lindgren A, et al.: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825–831.

33. Mueller J, Werner M, Siewert JR: Malignant progression in Barrett’s esophagus: Pathology and molecular biology. Recent Results Cancer Res 2000;155:29–41.

34. Lepage C, Rachet B, Jooste V, et al.: Continuing rapid increase in esophageal adenocarcinoma of the distal esophagus (Barrett adenocarcinoma of the distal esophagus (Barrett esophagus)). World J Surg 2013;37:728–733.

35. Wijetunge S, Ma Y, DeMeester SR, et al.: Association of Barrett oesophagogastric junction. Br J Surg 2012;99:1514–1521.

36. Siewert JR, Stein HJ, Feith M: Adenocarcinoma of the esophagogastric junction. Scand J Surg 2006;95:260–269.

37. Nieveen van Dijkum EJ, Sturin PD, de Wit LT, et al.: Cytology of peritoneal lavage performed during staging laparoscopy for gastrointestinal malignancies: Is it useful? Ann Surg 1998;228:728–733.

Journal of Surgical Oncology